Eloxx Pharmaceuticals in the spotlight (part III)
Eloxx (ELOX) provided a Q2 business update earlier this week, and everything was on schedule. Based on enrollment at the end of June, the company remains on track to report monotherapy data from the ongoing Phase 2 cystic fibrosis study in Q4 2021. We think data will be in November (details in our prior posts — part I and part II).
The Phase 2 monotherap…